Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

778
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
778
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Cancer Therapies02:49

Cancer Therapies

8.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.8K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

37
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
37

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploratory comparison of PASC and SARS-CoV-2 infection through metabolomics and lipidomics in early pandemic and Omicron-era.

Biochemistry and biophysics reports·2026
Same author

CCL19<sup>+</sup> fibroblasts define a proliferative niche in chronic lymphocytic leukemia.

bioRxiv : the preprint server for biology·2026
Same author

Identification and structural analysis of a novel FUT1 c.789C>A variant and previously reported para-Bombay alleles using an α2FucT1 structural model.

Transfusion·2026
Same author

The "next" standard for ABO genotyping.

Human immunology·2026
Same author

Plasmodium gets inside through the back door.

Blood·2026
Same author

Red blood cell transfusion survival in sickle cell disease is reduced by donor characteristics and recipient spleen activity.

Blood advances·2026

Related Experiment Video

Updated: Oct 26, 2025

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.5K

Daratumumab: Beyond Multiple Myeloma.

Kiran Ejaz1, John D Roback2, Sean R Stowell2

  • 1Department of Cardiology, Emory University School of Medicine, Atlanta, GA, USA.

Transfusion Medicine Reviews
|July 27, 2021
PubMed
Summary
This summary is machine-generated.

Daratumumab (DARA), a CD38-targeting antibody, shows promise beyond multiple myeloma. This review explores its potential in treating various antibody-mediated disorders by modulating the immune system.

Keywords:
AntibodiesCD38 antigen (p45) proteinMonoclonalplasma cells

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.6K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.6K

Related Experiment Videos

Last Updated: Oct 26, 2025

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.5K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.6K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.6K

Area of Science:

  • Immunology
  • Hematology
  • Pharmacology

Background:

  • Daratumumab (DARA) is a first-in-class human monoclonal antibody targeting CD38.
  • It is approved for multiple myeloma and investigated in other hematologic malignancies.
  • CD38 is expressed on plasma cells (PC) and plasma blasts.

Purpose of the Study:

  • To review the current literature on Daratumumab (DARA) applications outside of multiple myeloma and hematologic diseases.
  • To explore DARA's role as an immunologic modulator in antibody-mediated disorders.
  • To summarize case reports and series on DARA's use in diverse antibody-mediated conditions.

Main Methods:

  • Literature review of case reports and case series.
  • Analysis of DARA's mechanism of action as an immunologic modulator.
  • Synthesis of evidence for DARA's efficacy in antibody-mediated diseases.

Main Results:

  • Daratumumab (DARA) has demonstrated potential in treating various antibody-mediated disorders.
  • Case studies indicate DARA's effectiveness in conditions beyond its approved indications.
  • The immunomodulatory properties of DARA are being explored for novel therapeutic uses.

Conclusions:

  • Daratumumab (DARA) offers a potential therapeutic strategy for a range of antibody-mediated diseases.
  • Further research is warranted to establish DARA's efficacy and safety in non-hematologic, antibody-mediated conditions.
  • DARA represents a promising therapeutic option for antibody-driven pathologies.